The effect of improving the bone density at the surrounding total knee arthroplasty by Human Parathyroid Hormone (PTH)

The effect of improving the bone density at the surrounding total knee arthroplasty by Human Parathyroid Hormone (PTH) - The effect of improving the bone density at the surrounding TKA by PTH

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014074

Enrollment

Registered

2014-05-26

Start date

2014-04-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Human Parathyroid Hormone is administered by subctaneous injection(20 microgram with single daily dosing during 2 year or 56.5 microgram with single weekly dosing during 1.5 year)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Osteoporosis patient who is postoperative total knee arthroplasty and administered the Human Parathyroid Hormone. 2)Patient who is a subject of the present study and consented to the data provided.

Exclusion criteria

Exclusion criteria: 1)Patient who is suspected of being pregnant or pregnant women 2)Patient who is difficult to communicate

Design outcomes

Primary

Measure	Time frame
Investigation of improvement effect the bone atrophy of surround the artificial knee joint by Human Parathyroid Hormone	—

Secondary

Measure	Time frame
Investigation of improvement effect on the clinical evaluation of osteoporosis or knee joint by Human Parathyroid Hormone	—

Countries

Japan

Contacts

Public ContactFumio Sukesaki

Showa university Hospital Orthopedics

tatsuyawahaha@yahoo.co.jp03-3784-8543

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026